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Abstracts
Gregory L. Moneta, MD, Section EditorRevised Cardiac Risk Index (Lee) and Perioperative Cardiac Events as
Predictors of Long-Term Mortality in Patients Undergoing Endovas-
cular Abdominal Aortic Aneurysm Repair
Archan S, Roscher CR, Fairman RM, et al. J Cardiothorac Vasc Anesthesia
2010;24:84-90.
Conclusion: Long-term mortality is high after endovascular repair of
abdominal aortic aneurysm (AAA). In the setting of endovascular AAA
repair, the Lee Index may be useful for stratifying short-term and long-term
mortality in high-risk patients.
Summary: Perioperative myocardial infarction remains a vexing prob-
lem. In very high-risk vascular surgical patients, perioperative myocardial
ischemic injury may be as high as 18% to 35% (J Vasc Surg 2006;43:533-
538). Although a large majority of patients survive a perioperative myocar-
dial ischemic event, they are at risk of increased late mortality (J Vasc Surg
1994;20:598-604). Because it appears long-term survival is not improved by
endovascular aneurysm repair (EVAR) vs conventional open AAA repair, it is
reasonable to investigate whether patients undergoing EVAR can be strati-
fied according to the Revised Cardiac Risk Index (Lee). This was a retro-
spective review from a single academic medical center involving 225 patients
with AAA treated with EVAR between 1999 and 2006. The goal was to
determine if the Lee Index is useful is stratifying patients by risk of both
perioperative cardiacmorbidity and long-term all-causemortality. Data were
collected from physician quality assurance databases, office records, and
medical records. There were no in-hospital cardiac deaths. Themajor cardiac
adverse event (MACE) rate perioperatively was 6.2%. Long-term all-cause
mortality was 23%. By univariate analysis, a history of coronary artery disease
(likelihood ratio [LR], 8.7; P  .023), history of congestive heart failure
(LR, 4; P  .042), and a Revised Cardiac Risk Index (RCRI) 3 (LR, 8.6;
P  .004) were all predictors of perioperative MACE. Long-term all-cause
mortality was associated with a history of coronary artery disease (LR, 10.7;
P .002), perioperative cardiac events (LR, 15.9; P .0001), echocardio-
graphic evidence of myocardial infarction (LR, 8.5; P  .006), and exercise
tolerance of only on block (LR, 8.4; P  .005). Long-term mortality is
increased after perioperative cardiac events within the RCRI 3 subgroup
(LR, 6.1; P  .019).
Comment: It would seem logical that a patient who develops a
myocardial ischemic event after EVAR should undergo further evaluation
for coronary artery disease. Long-term survival appears significantly im-
paired after EVAR, and more so after even a minor myocardial infarction
following EVAR. Whether the minor perioperative myocardial event is a
cause of long-term mortality or merely a marker of long-term increased
cardiac risk is a question that deserves further investigation.
Eligibility for Statin Therapy by the JUPITER Trial Criteria and
Subsequent Mortality
Cushman M, McClure LA, Lakoski SG, et al. Am J Cardiol 2010;105:
77-81.
Conclusion: Applying JUPITER trial eligibility criteria, 21% of pa-
tients not eligible for lipid-lowering therapy by the guidelines proposed by
the National Cholesterol Education Program (NCEP) Adult Treatment
Panel (ATP) would be eligible for lipid-lowering therapy based on
JUPITER trial eligibility.
Summary: The JUPITER trial reported that individuals without dia-
betes who were not eligible for lipid-lowering therapy by traditional guide-
lines, but who had C-reactive protein levels (CRP) 2.0 mg/L, had a 20%
reduction in all cause mortality and a 44% reduction in vascular events with
rosuvastatin treatment compared with placebo. Patients were eligible for
JUPITER if they had a low-density lipoprotein cholesterol (LDL-C) level
130 mg/dL, no diabetes, no concurrent use of hormone replacement
therapy, a creatinine 2 mg/dL, and triglycerides 500 mg/dL. The
NCEP ATP (JAMA 2001;285:2486-97) has suggested strategies for pri-
mary prevention of coronary heart disease are appropriate in persons with
high levels of LDL-C (160 mg/dL) or those with borderline high LDL-C
(130-159 mg/dL) and multiple (2) risk factors. Therefore, patients eligi-
ble for JUPITER, inmany cases, would not be suggested for statin treatment
by the ATP III guidelines. The authors therefore sought to evaluate the
effect of applying JUPITER criteria vs those suggested by ATP III guidelines
to the general population. The study group consisted of 3229 participants in
the REasons for Geographic and Racial Differences in Stroke (REGARDS)
cohort. This is an observation study of white and African Americans aged
45 years. Fifty-six percent of the sample resides in the 10 southern “stroke
belt” states, with the rest from the other 38 contiguous states. Among
11,339 participants age-eligible for JUPITER and without a vascular diag-
518nosis or using lipid-lower therapy, 2342 (21%) met JUPITER criteria.
Compared with participants in the JUPITER study, they had similar LDL-C
and CRP levels, were more often women, black, and had metabolic syndrome.
At 3.5 years of follow-up, the mortality rate in REGARDS participants eligible
for JUPITER was 1.17 per 100 patient-years (95% CI, 0.94-1.42). Compared
with those who were otherwise eligible for JUPITER who had CRP levels2
mg/L (n  2620), those with CRP levels 2 mg/L had an adjusted relative
total mortality risk of 1.5 (95% CI, 1.1-2.2).
Comment: The implication of the article is that CRP testing should be
added to risk stratification of vascular disease and that many thousands of
patients potentially benefiting from statin therapy are not being offered
treatment. Almost half of REGARDS participants eligible for JUPITER on
the basis of clinical factors before CRP testing were eligible on the basis of
having CRP levels2mg/L. REGARDS participants eligible for JUPITER,
who did not meet ATP III guidelines for lipid lowering but who had a CRP
level2 mg/L, had a 50% greater mortality than those with CRP levels2
mg/L. The bottom line is that if JUPITER criteria are applied for applica-
tion of lipid-lowering therapy, twice as many individuals would be eligible
for lipid-lowering therapy compared with those eligible by ATP III guide-
lines.
Long-Term Outcome of Open or Endovascular Repair of Abdominal
Aortic Aneurysm
De Bruin JL, Baas AF, Buth J, and the DREAMStudy Group. N Engl JMed
2010;362:1881-9.
Conclusions: Long-term survival after open and endovascular abdom-
inal aortic aneurysm (AAA) repair is the same, but endovascular repair is
more expensive and is associated with more reinterventions.
Summary: These are 6-year outcome data of the DREAM trial, a
long-term multicenter, randomized, controlled trial comparing open repair
with endovascular repair in 351 patients with AAAs 5 cm in diameter.
Patients were considered suitable candidates for either open or endovascular
repair. The primary outcomes were rates of death from any cause and
reintervention. This article appeared in the same issue of the New England
Journal of Medicine as the long-term results of EVAR 1 and EVAR 2 and
provides additional long-term follow-up of the effectiveness and durability
of endovascular AAA repair. (The 2-year data were published in 2005 by
Blankensteijn JD, et al, N Engl J Med 2005;352:2398-405). A total of 173
patients were randomized to undergo endovascular repair, and 178 were
assigned to open repair. Kaplan-Meier methods were used to calculate
survival on an intention-to-treat basis. At 6 years after randomization,
cumulative survival rates for open and endovascular repair were 69.9% and
68.9%, respectively (difference, 1.0 percentage point; 95% CI, 1.8 to 10.8;
P  .97). Cumulative rates of freedom from secondary intervention were
81.9% for open repair and 70.4% for endovascular repair (difference, 11.5
percentage points; 95% CI, 2.0-21.0; P  .03).
Comment: The results of this study mirror very closely the long-term
results of EVAR 1 (N Engl J Med 2010;362:1863-71). Like EVAR 1,
DREAM concluded there is no long-term survival advantage of endovascu-
lar repair vs open repair for AAA, and endovascular repair is more expensive
and requires more reinterventions. However, despite lack of long-term
efficacy of endovascular repair compared with open repair, physicians and
patients both like endovascular repair. In effect, this genie is already out of
the bottle. These data and data from EVAR 1 should provide material for
surgeons to have open and objective discussions with their patients about
alternatives for treatment of AAA. It remains to be seen whether payers will
begin to demand justification for endovascular repair over an open proce-
dure. Logically, it seems they could and perhaps should.
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration. JAMA 2009;302:1993-2000.
Conclusion: It is possible to simplify lipid assessment in vascular
disease by measuring either total high-density lipoprotein (HDL) choles-
terol (HDL-C) levels or apolipoproteins. It is not necessary to fast or
measure triglyceride levels.
Summary: There is a disagreement among lipid experts about whether
assessment of apolipoprotein A1 (apo A1), and apolipoprotein B (apo B),
should replace assessment of HDL-C and total cholesterol levels for assess-
ment of vascular risk. Although there is agreement on the value of reducing
low-density lipoprotein cholesterol (LDL-C) it is unclear whether there is
benefit in modification or measurement of triglycerides or HDL-C (JAMA
2001;285:2486-97). In addition, failure of torcetrapib has led to questions
